Current research on pharmacologic and regenerative therapies for osteoarthritis

Bone Research

Volumn 4, Issue , 2016, Pages

  Zhang, Wei ^a,b   Ouyang, Hongwei ^a   Dass, Crispin R ^c   Xu, Jiake ^b  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c CURTIN UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84959260064     PISSN: 20954700     EISSN: 20956231     Source Type: Journal    
DOI: 10.1038/boneres.2015.40     Document Type: Review

References (146)

1. Zhang Y, Jordan JM. Epidemiology of osteoarthritis. Clin Geriatr Med 2010; 26: 355-369.
2. Felson DT. Clinical practice. osteoarthritis of the knee. N Engl J Med 2006; 354: 841-848
3. Zhang W, Moskowitz RW, Nuki G et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008; 16: 137-162
4. Hochberg MC, Dougados M. Pharmacological therapy of osteoarthritis. Best Pract Res Clin Rheumatol 2001; 15: 583-593
5. Lanza R, Langer R, Vacanti JP. Principles of Tissue Engineering. 3rd edn. Academic Press: Burlington, VT, USA. 2011.
6. Pearle AD, Warren RF, Rodeo SA. Basic science of articular cartilage and osteoarthritis. Clin Sports Med 2005; 24: 1-12
7. Hunter W. Of the structure and diseases of articulating cartilages, by William Hunter, Surgeon. Phil. Trans 1742; 42: 514-521
8. Gilbert JE. Current treatment options for the restoration of articular cartilage. Am J Knee Surg 1998; 11: 42-46
9. Hunziker EB. Articular cartilage repair: basic science and clinical progress. A review of the current status and prospects. Osteoarthritis Cartilage 2002; 10: 432-463
10. Brocklehurst R, Bayliss MT, Maroudas A et al. The composition of normal and osteoarthritic articular cartilage from human knee joints. With special reference to unicompartmental replacement and osteotomy of the knee. J Bone Joint Surg Am 1984; 66: 95-106
11. Venn M, Maroudas A. Chemical composition and swelling of normal and osteoarthrotic femoral head cartilage. I. Chemical composition. Ann Rheum Dis 1977; 36: 121-129
12. Sandell LJ, Aigner T. Articular cartilage and changes in arthritis. An introduction: cell biology of osteoarthritis. Arthritis Res 2001; 3: 107-113
13. Khan IM, Williams R, Archer CW. One flew over the progenitor's nest: migratory cells find a home in osteoarthritic cartilage. Cell Stem Cell 2009; 4: 282-284
14. Del CMJ, Loeser RF. Cell death in osteoarthritis. Curr Rheumatol Rep 2008; 10: 37-42
15. Dreier R. Hypertrophic differentiation of chondrocytes in osteoarthritis: the developmental aspect of degenerative joint disorders. Arthritis Res Ther 2010; 12: 216
16. van den Berg WB. Osteoarthritis year 2010 in review: pathomechanisms. Osteoarthritis Cartilage 2011; 19: 338-341
17. Ea HK, Nguyen C, Bazin D et al. Articular cartilage calcification in osteoarthritis: insights into crystal-induced stress. Arthritis Rheum 2011; 63: 10-18
18. Fuerst M, Bertrand J, Lammers L et al. Calcification of articular cartilage in human osteoarthritis. Arthritis Rheum 2009; 60: 2694-2703
19. van der Kraan PM, van den Berg WB. Osteophytes: relevance and biology. Osteoarthritis Cartilage 2007; 15: 237-244
20. Felson DT, Gale DR, Elon GM et al. Osteophytes and progression of knee osteoarthritis. Rheumatology (Oxford) 2005; 44: 100-104
21. Hayami T, Pickarski M, Zhuo Y et al. Characterization of articular cartilage and subchondral bone changes in the rat anterior cruciate ligament transection and meniscectomized models of osteoarthritis. Bone 2006; 38: 234-243
22. Dixon AS, Jacoby RK, Berry H et al. Clinical trial of intra-articular injection of sodium hyaluronate in patients with osteoarthritis of the knee. Curr Med Res Opin 1988; 11: 205-213
23. Benito MJ, Veale DJ, FitzGerald O et al. Synovial tissue inflammation in early and late osteoarthritis. Ann Rheum Dis 2005; 64: 1263-1267
24. Treatment of Osteoarthritis of the Knee. 2nd edn. Rosemont: American Academy of Orthopaedic Surgeons, 2013.
25. Felson DT, Zhang Y, Hannan MT et al. Risk factors for incident radiographic knee osteoarthritis in the elderly: the framingham study. Arthritis Rheum 1997; 40: 728-733
26. Creamer P, Hochberg MC. Osteoarthritis. Lancet 1997; 350: 503-508
27. Christensen R, Astrup A, Bliddal H. Weight loss: the treatment of choice for knee osteoarthritis? A Randomized trial. Osteoarthritis Cartilage 2005; 13: 20-27
28. Roddy E, Zhang W, Doherty M. Aerobic walking or strengthening exercise for osteoarthritis of the knee? A systematic review. Ann Rheum Dis 2005; 64: 544-548
29. van Baar ME, Dekker J, Oostendorp RA et al. The effectiveness of exercise therapy in patients with osteoarthritis of the hip or knee: a randomized clinical trial. J Rheumatol 1998; 25: 2432-2439
30. Ernst E, Posadzki P. Complementary and alternative medicine for rheumatoid arthritis and osteoarthritis: an overview of systematic reviews. Curr Pain Headache Rep 2011; 15: 431-437
31. De Luigi AJ. Complementary and alternative medicine in osteoarthritis. PM R 2012; 4: S122-S133
32. Dervin GF, Stiell IG, Rody K et al. Effect of arthroscopic debridement for osteoarthritis of the knee on health-related quality of life. J Bone Joint Surg Am 2003; 85-A: 10-19
33. Laupattarakasem W, Laopaiboon M, Laupattarakasem P et al. Arthroscopic debridement for knee osteoarthritis. Cochrane Database Syst Rev 2008, D5118.
34. Knutsen G, Drogset JO, Engebretsen L et al. A randomized trial comparing autologous chondrocyte implantation with microfracture. findings at five years. J Bone Joint Surg Am 2007; 89: 2105-2112
35. Saris DB, Vanlauwe J, Victor J et al. Characterized chondrocyte implantation results in better structural repair when treating symptomatic cartilage defects of the knee in a randomized controlled trial versus microfracture. Am J Sports Med 2008; 36: 235-246
36. Malchau H, Herberts P, Eisler T et al. The Swedish total hip replacement register. J Bone Joint Surg Am 2002; 85-A Suppl 2: 2-20
37. Grayson CW, Decker RC. Total joint arthroplasty for persons with osteoarthritis. PM R 2012; 4: S97-S103
38. Mason C, Dunnill P. A brief definition of regenerative medicine. Regen Med 2008; 3: 1-5
39. Tang QO, Carasco CF, Gamie Z et al. Preclinical and clinical data for the use of mesenchymal stem cells in articular cartilage tissue engineering. Expert Opin Biol Ther 2012; 12: 1361-1382
40. Davatchi F, Abdollahi BS, Mohyeddin M, Shahram F, Nikbin B. Mesenchymal stem cell therapy for knee osteoarthritis. Preliminary report of four patients. Int J Rheum Dis 2011; 14: 211-215
41. Orozco L, Munar A, Soler R et al. Treatment of knee osteoarthritis with autologous mesenchymal stem cells: a pilot study. Transplantation 2013; 95: 1535-1541
42. Koh YG, Jo SB, Kwon OR et al. Mesenchymal stem cell injections improve symptoms of knee osteoarthritis. Arthroscopy 2013; 29: 748-755
43. Bauer S, Khan RJ, Ebert JR et al. Knee joint preservation with combined neutralising high tibial osteotomy (HTO) and matrix-induced autologous chondrocyte implantation (MACI) in younger patients with medial knee osteoarthritis: a case series with prospective clinical and MRI follow-up over 5 years. Knee 2012; 19: 431-439
44. Ossendorf C, Kaps C, Kreuz PC et al. Treatment of posttraumatic and focal osteoarthritic cartilage defects of the knee with autologous polymer-based three-dimensional chondrocyte grafts: 2-year clinical results. Arthritis Res Ther 2007; 9: R41.
45. Kreuz PC, Muller S, Ossendorf C et al. Treatment of focal degenerative cartilage defects with polymer-based autologous chondrocyte grafts: four-year clinical results. Arthritis Res Ther 2009; 11: R33.
46. Kon E, Delcogliano M, Filardo G et al. Novel nano-composite multilayered biomaterial for the treatment of multifocal degenerative cartilage lesions. Knee Surg Sports Traumatol Arthrosc 2009; 17: 1312-1315
47. Siclari A, Mascaro G, Gentili C et al. A cell-free scaffold-based cartilage repair provides improved function hyaline-like repair at one year. Clin Orthop Relat Res 2012; 470: 910-919
48. Zhang W, Moskowitz RW, Nuki G et al. OARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthritis Cartilage 2007; 15: 981-1000
49. Hochberg MC, Altman RD, April KT et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken) 2012 64: 465-474
50. Schiodt FV, Rochling FA, Casey DL et al. Acetaminophen toxicity in an urban county hospital. N Engl J Med 1997; 337: 1112-1117
51. Black M. Acetaminophen hepatotoxicity. Annu Rev Med 1984; 35: 577-593
52. US Food and Drug Administration. FDA Limits Acetaminophen in Prescription Combination Products; Requires Liver Toxicity Warnings. Silver Spring: FDA, 2011. Available at http://www.fda.gov/NewsE vents/Newsroom/PressAnnouncements/ucm239894.htm. 25 September 2015.
53. Zhang W, Jones A, Doherty M. Does paracetamol (acetaminophen) reduce the pain of osteoarthritis? A meta-analysis of randomised controlled trials. Ann Rheum Dis 2004; 63: 901-907
54. Towheed TE, Maxwell L, Judd MG et al. Acetaminophen for osteoarthritis. Cochrane Database Syst Rev 2006, D4257.
55. Pirmohamed M, James S, Meakin S et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004; 329: 15-19
56. Garcia RL, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343: 769-772
57. Langman MJ, Weil J, Wainwright P et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343: 1075-1078
58. US Food and Drug Administration Information for Healthcare Professionals: Celecoxib (marketed as Celebrex). Silver Spring: FDA, 2005. Available at http://www.fda.gov/Drugs/DrugSafety/Postmarket DrugSafetyInformationforPatientsandProviders/ucm124655.htm. 25 September 2015.
59. US Food and Drug Administration. FDA Public Health Advisory: Safety of Vioxx. Silver Spring: FDA, 2004. Available at http://www. fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatients andproviders/ucm106274.htm. 25 September 2015.
60. US Food and Drug Administration. Information for Healthcare Professionals: Valdecoxib (marketed as Bextra). Silver Spring: FDA, 2005. Available at http://www.fda.gov/Drugs/DrugSafety/Postmarket DrugSafetyInformationforPatientsandProviders/ucm124649.htm. 25 September 2015.
61. Wright EA, Katz JN, Abrams S et al. Trends in prescription of opioids from 2003-2009 in persons with knee osteoarthritis. Arthritis Care Res (Hoboken) 2014; 66: 1489-1495
62. Beaulieu AD, Peloso PM, Haraoui B et al. Once-daily, controlled-release tramadol and sustained-release diclofenac relieve chronic pain due to osteoarthritis: a randomized controlled Trial. Pain Res Manag 2008; 13: 103-110
63. Gana TJ, Pascual ML, Fleming RR et al. Extended-release tramadol in the treatment of osteoarthritis: a multicenter, randomized, doubleblind, placebo-controlled clinical trial. Curr Med Res Opin 2006; 22: 1391-1401
64. DeLemos BP, Xiang J, Benson C et al. Tramadol hydrochloride extended-release once-daily in the treatment of osteoarthritis of the knee and/or hip: a double-blind, randomized, dose-ranging trial. Am J Ther 2011; 18: 216-226
65. US Food and Drug Administration. FDA Clears Cymbalta to Treat Chronic Musculoskeletal Pain. Silver Spring: FDA, 2010. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm232708.htm. 25 September 2015.
66. Chappell AS, Desaiah D, Liu-Seifert H et al. A double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee. Pain Pract 2011; 11: 33-41
67. Chappell AS, Ossanna MJ, Liu-Seifert H et al. Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial. Pain 2009; 146: 253-260
68. Noth U, Steinert AF, Tuan RS. Technology insight: adult mesenchymal stem cells for osteoarthritis therapy. Nat Clin Pract Rheumatol 2008; 4: 371-380
69. Ong KL, Villarraga ML, Lau E et al. Off-label use of bone morphogenetic proteins in the United States using administrative data. Spine (Phila Pa 1976) 2010; 35: 1794-1800
70. Hunter DJ, Pike MC, Jonas BL et al. Phase 1 Safety and tolerability study of BMP-7 in symptomatic knee osteoarthritis. BMC Musculoskelet Disord 2010; 11: 232.
71. Chevalier X, Goupille P, Beaulieu AD et al. Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, doubleblind, placebo-controlled study. Arthritis Rheum 2009; 61: 344-352
72. Cohen SB, Proudman S, Kivitz AJ et al. A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1R1) in patients with osteoarthritis of the knee. Arthritis Res Ther 2011; 13: R125.
73. Lane NE, Schnitzer TJ, Birbara CA et al. Tanezumab for the treatment of pain from osteoarthritis of the knee. N Engl J Med 2010; 363: 1521-1531
74. US Food and Drug Administration. Tanezumab Arthritis Advisory Committee Briefing Document. Silver Spring: FDA, 2012. Available at http://www.fda.gov/downloads/AdvisoryCommittees/Committees MeetingMaterials/Drugs/ArthritisAdvisoryCommittee/UCM295205.pdf. 25 September 2015.
75. Seidel MF, Lane NE. Control of arthritis pain with anti-nerve-growth factor: risk and benefit. Curr Rheumatol Rep 2012; 14: 583-588
76. Lohmander LS, Hellot S, Dreher D et al. Intraarticular sprifermin (recombinant human fibroblast growth factor 18) in knee osteoarthritis: a randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol 2014; 66: 1820-1831
77. Sánchez M, Anitua E, Azofra J et al. Intra-articular injection of an autologous preparation rich in growth factors for the treatment of knee oa: a retrospective cohort study. Clin Exp Rheumatol 2008; 26: 910-913
78. Wang-Saegusa A, Cugat R, Ares O et al. Infiltration of plasma rich in growth factors for osteoarthritis of the knee short-term effects on function and quality of life. Arch Orthop Trauma Surg 2011; 131: 311-317
79. Sampson S, Reed M, Silvers H et al. Injection of platelet-rich plasma in patients with primary and secondary knee osteoarthritis: a pilot study. Am J Phys Med Rehabil 2010; 89: 961-969
80. Kon E, Buda R, Filardo G et al. Platelet-rich plasma: intra-articular knee injections produced favorable results on degenerative cartilage lesions. Knee Surg Sports Traumatol Arthrosc 2010; 18: 472-479
81. Shimonkevitz R, Thomas G, Slone DS et al. A diketopiperazine fragment of human serum albumin modulates t-lymphocyte cytokine production through Rap1. J Trauma 2008; 64: 35-41
82. Bar-Or D, Salottolo KM, Loose H et al. A randomized clinical trial to evaluate two doses of an intra-articular injection of LMWF-5A in adults with pain due to osteoarthritis of the knee. Plos One 2014; 9: e87910.
83. Ampio Pharmaceuticals Inc. Results from the 20 Weeks Extension of the Ampion SPRING Study to be Presented at the Western Orthopedic Association Conference. Englewood: Ampio Pharmaceuticals Inc., 2014. Available at http://ampiopharma.com/news/results-20-weeksextension-ampiontm-spring-study-presented-western-orthopedic-asso ciation-conference. 25 September 2015.
84. Ampio Pharmaceuticals Inc. Ampio Announces Top-Line Results of the Double-Blind Multiple Intra-Articular Injections (STRUT) Study of AmpionTM in Patients with Moderate to Severe Osteoarthritis of the Knee. Englewood: Ampio Pharmaceuticals Inc., 2015. Available at http://ampiopharma.com/news/ampio-announces-top-line-results-ofthe-double-blind-multiple-intra-articular-injections-strut-study-of-ampionin-patients-with-moderate-to-severe-osteoarthritis-of-the-knee/. 25 September 2015.
85. Wenham CY, Grainger AJ, Hensor EM et al. Methotrexate for pain relief in knee osteoarthritis: an open-label study. Rheumatology (Oxford) 2013; 52: 888-892
86. Kingsbury SR, Tharmanathan P, Arden NK et al. Pain reduction with oral methotrexate in knee osteoarthritis, a pragmatic phase iii trial of treatment effectiveness (PROMOTE): study protocol for a randomized controlled trial. Trials 2015; 16: 77.
87. ISRCTN Registry. Pain Reduction with Oral Methotrexate in Knee Osteoarthritis: A Pragmatic Phase III Trial of Treatment Effectiveness. London: BioMed Central, 2015. Available at http://www.controlledtrials. com/ISRCTN77854383. 25 September 2015.
88. Abou-Raya A, Abou-Raya S, Khadrawe T. Methotrexate in the treatment of symptomatic knee osteoarthritis: randomised placebocontrolled trial. Ann Rheum Dis 2014. doi: 10.1136/annrheumdis-2013-204856. [Epub ahead of print].
89. Jiang YZ, Zhang SF, Qi YY et al. Cell transplantation for articular cartilage defects: principles of past, present, and future practice. Cell Transplant 2011; 20: 593-607
90. Brittberg M, Lindahl A, Nilsson A et al. Treatment of deep cartilage defects in the knee with autologous chondrocyte transplantation. N Engl J Med 1994; 331: 889-895
91. Tuan RS. A second-generation autologous chondrocyte implantation approach to the treatment of focal articular cartilage defects. Arthritis Res Ther 2007; 9: 109.
92. Marlovits S, Zeller P, Singer P et al. Cartilage repair: generations of autologous chondrocyte transplantation. Eur J Radiol 2006; 57: 24-31
93. Peterson L, Minas T, Brittberg M et al. Treatment of osteochondritis dissecans of the knee with autologous chondrocyte transplantation: results at two to ten years. J Bone Joint Surg Am 2003; 85-A Suppl 2: 17-24
94. Peterson L, Minas T, Brittberg M et al. Two-to 9-year outcome after autologous chondrocyte transplantation of the knee. Clin Orthop Relat Res 2000: 212-234
95. US Food and Drug Administration. 22 August 22 1997 Approval Letter -Carticel. Rockville: FDA, 1997. Available at http://www.fda.gov/ BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedPro ducts/ucm171702.htm. 25 September 2015.
96. Knutsen G, Engebretsen L, Ludvigsen TC et al. Autologous chondrocyte implantation compared with microfracture in the knee. A randomized trial. J Bone Joint Surg Am 2004; 86-A: 455-464
97. Marcacci M, Kon E, Grigolo B et al. 8.3 The clinician view. Osteoarthr Cartilage 2007; 15: B11-B13
98. Gomoll AH, Filardo G, de Girolamo L et al. Surgical treatment for early osteoarthritis. Part I: cartilage repair procedures. Knee Surg Sports Traumatol Arthrosc 2012; 20: 450-466
99. Rosenberger RE, Gomoll AH, Bryant T et al. Repair of large chondral defects of the knee with autologous chondrocyte implantation in patients 45 years or older. Am J Sports Med 2008; 36: 2336-2344
100. Minas T, Gomoll AH, Solhpour S et al. Autologous chondrocyte implantation for joint preservation in patients with early osteoarthritis. Clin Orthop Relat Res 2010; 468: 147-157
101. Matricali GA, Dereymaeker GP, Luyten FP. Donor site morbidity after articular cartilage repair procedures: a review. Acta Orthop Belg 2010; 76: 669-674
102. Schnabel M, Marlovits S, Eckhoff G et al. Dedifferentiation-associated changes in morphology and gene expression in primary human articular chondrocytes in cell culture. Osteoarthritis Cartilage 2002; 10: 62-70
103. Mackay AM, Beck SC, Murphy JM et al. Chondrogenic differentiation of cultured human mesenchymal stem cells from marrow. Tissue Eng 1998; 4: 415-428
104. Lee RH, Kim B, Choi I et al. Characterization and expression analysis of mesenchymal stem cells from human bone marrow and adipose tissue. Cell Physiol Biochem 2004; 14: 311-324
105. De Bari C, Dell'Accio F, Tylzanowski P et al. Multipotent mesenchymal stem cells from adult human synovial membrane. Arthritis Rheum 2001; 44: 1928-1942
106. Koh YG, Choi YJ. Infrapatellar fat pad-derived mesenchymal stem cell therapy for knee osteoarthritis. Knee 2012; 19: 902-907
107. Temenoff JS, Mikos AG. Review: tissue engineering for regeneration of articular cartilage. Biomaterials 2000; 21: 431-440
108. Daher RJ, Chahine NO, Greenberg AS et al. New methods to diagnose and treat cartilage degeneration. Nat Rev Rheumatol 2009; 5: 599-607
109. Schinhan M, Gruber M, Dorotka R et al. Matrix-associated autologous chondrocyte transplantation in a compartmentalized early stage of osteoarthritis. Osteoarthritis Cartilage 2013; 21: 217-225
110. Evans CH, Ghivizzani SC, Robbins PD. Getting arthritis gene therapy into the clinic. Nat Rev Rheumatol 2011; 7: 244-249
111. US National Institutes of Health. Safety Study of TissueGene-C in Degenerative Joint Disease of the Knee (TGC-03-01). Bethesda: Clinical Trials.gov, 2010. Available at http://clinicaltrials.gov/ct2/show/ NCT00599248. 25 September 2015.
112. US National Institutes of Health. Efficacy and Safety Study of TissueGene-C to Degenerative Arthritis. Bethesda: ClinicalTrials.gov, 2015. Available at http://clinicaltrials.gov/ct2/show/NCT01671072. 25 September 2015.
113. Ha CW, Noh MJ, Choi KB et al. Initial phase I safety of retrovirally transduced human chondrocytes expressing transforming growth factorbeta-1 in degenerative arthritis patients. Cytotherapy 2012; 14: 247-256
114. Ha C, Park SH, Cho JJ et al. A phase IIA clinical study of tissuegene-C (TGC) in patients with osteoarthritis. Osteoarthr Cartilage 2012; 20: S27-S28
115. US National Institutes of Health. Efficacy and Safety Study of TissueGene-C to Degenerative Arthritis. Bethesda: ClinicalTrials.gov, 2015. Available at http://clinicaltrials.gov/ct2/show/NCT02072070. 25 September 2015.
116. Zhu M, Tang D, Wu Q et al. Activation of beta-catenin signaling in articular chondrocytes leads to osteoarthritis-like phenotype in adult beta-catenin conditional activation mice. J Bone Miner Res 2009; 24: 12-21
117. Shen J, Li J, Wang B et al. Deletion of the transforming growth factor beta receptor type ii gene in articular chondrocytes leads to a progressive osteoarthritis-like phenotype in mice. Arthritis Rheum 2013; 65: 3107-3119
118. Wang M, Sampson ER, Jin H et al. MMP13 is a critical target gene during the progression of osteoarthritis. Arthritis Res Ther 2013; 15: R5.
119. Chen P, Zhu S, Wang Y et al. The amelioration of cartilage degeneration by ADAMTS-5 inhibitor delivered in a hyaluronic acid hydrogel. Biomaterials 2014; 35: 2827-2836
120. Echtermeyer F, Bertrand J, Dreier R et al. Syndecan-4 regulates ADAMTS-5 activation and cartilage breakdown in osteoarthritis. Nat Med 2009; 15: 1072-1076
121. Krzeski P, Buckland-Wright C, Balint G et al. Development of musculoskeletal toxicity without clear benefit after administration of PG--116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebocontrolled study. Arthritis Res Ther 2007; 9: R109.
122. Zhang W, Chen J, Zhang S et al. Inhibitory function of parathyroid hormone-related protein on chondrocyte hypertrophy: the implication for articular cartilage repair. Arthritis Res Ther 2012; 14: 221.
123. Zhang W, Chen J, Tao J et al. The promotion of osteochondral repair by combined intra-articular injection of parathyroid hormone-related protein and implantation of a bi-layer collagen-silk scaffold. Biomaterials 2013; 34: 6046-6057
124. Vortkamp A, Lee K, Lanske B et al. Regulation of rate of cartilage differentiation by indian hedgehog and PTH-related protein. Science 1996; 273: 613-622
125. Chung UI, Lanske B, Lee K et al. The parathyroid hormone/parathyroid hormone-related peptide receptor coordinates endochondral bone development by directly controlling chondrocyte differentiation. Proc Natl Acad Sci USA 1998; 95: 13030-13035
126. Sampson ER, Hilton MJ, Tian Y et al. Teriparatide as a chondroregenerative therapy for injury-induced osteoarthritis. Sci Transl Med 2011; 3: 101r-193r
127. Lin AC, Seeto BL, Bartoszko JMet al. Modulating hedgehog signaling can attenuate the severity of osteoarthritis. Nat Med 2009; 15: 1421-1425
128. Ruiz-Heiland G, Horn A, Zerr P et al. Blockade of the hedgehog pathway inhibits osteophyte formation in arthritis. Ann Rheum Dis 2012; 71: 400-407
129. Zhen G, Wen C, Jia X et al. Inhibition of TGF-beta signaling in mesenchymal stem cells of subchondral bone attenuates osteoarthritis. Nat Med 2013; 19: 704-712
130. Lories RJ, Corr M, Lane NE. To Wnt or not to Wnt: the bone and joint health dilemma. Nat Rev Rheumatol 2013; 9: 328-339
131. Funck-Brentano T, Bouaziz W, Marty C et al. Dkk-1-mediated inhibition of Wnt signaling in bone ameliorates osteoarthritis in mice. Arthritis Rheumatol 2014; 66: 3028-3039
132. Trounson A. The production and directed differentiation of human embryonic stem cells. Endocr Rev 2006; 27: 208-219
133. Thomson JA, Itskovitz-Eldor J, Shapiro SS et al. Embryonic stem cell lines derived from human blastocysts. Science 1998; 282: 1145-1147
134. Kramer J, Hegert C, Guan K et al. Embryonic stem cell-derived chondrogenic differentiation in vitro: activation by BMP-2 and BMP-4. Mech Dev 2000; 92: 193-205
135. Yang Z, Sui L, Toh WS et al. Stage-dependent effect of TGF-beta1 on chondrogenic differentiation of human embryonic stem cells. Stem Cells Dev 2009; 18: 929-940
136. Wakitani S, Aoki H, Harada Y et al. Embryonic stem cells form articular cartilage, not teratomas, in osteochondral defects of rat joints. Cell Transplant 2004; 13: 331-336
137. Dattena M, Pilichi S, Rocca S et al. Sheep embryonic stem?like cells transplanted in full?thickness cartilage defects. J Tissue Eng Regen Med 2009; 3: 175-187
138. Alper J. Geron gets green light for human trial of ES cell-derived product. Nat Biotechnol 2009; 27: 213-214
139. Hackett CH, Fortier LA. Embryonic stem cells and iPS cells: sources and characteristics. Vet Clin North Am Equine Pract 2011; 27: 233.
140. Guzzo RM, Gibson J, Xu RH et al. Efficient differentiation of human iPSC?derived mesenchymal stem cells to chondroprogenitor cells. J Cell Biochem 2013; 114: 480-490
141. Tashiro K, Inamura M, Kawabata K et al. Efficient adipocyte and osteoblast differentiation from mouse induced pluripotent stem cells by adenoviral transduction. Stem Cells 2009; 27: 1802-1811
142. Tanaka T, Tohyama S, Murata M et al. In vitro pharmacologic testing using human induced pluripotent stem cell-derived cardiomyocytes. Biochem Biophys Res Commun 2009; 385: 497-502
143. Wei Y, Zeng W, Wan R et al. Chondrogenic differentiation of induced pluripotent stem cells from osteoarthritic chondrocytes in alginate matrix. Eur Cell Mater 2012; 23: 1-12
144. Chen FM, Wu LA, Zhang M et al. Homing of endogenous stem/ progenitor cells for in situ tissue regeneration: Promises, strategies, and translational perspectives. Biomaterials 2011; 32: 3189-3209
145. Zhang W, Chen J, Tao J et al. The use of type 1 collagen scaffold containing stromal cell-derived factor-1 to create a matrix environment conducive to partial-thickness cartilage defects repair. Biomaterials 2013; 34: 713-723
146. Chen J, Chen H, Li P et al. Simultaneous regeneration of articular cartilage and subchondral bone in vivo using MSCs induced by a spatially controlled gene delivery system in bilayered integrated scaffolds. Biomaterials 2011; 32: 4793-4805